To analyze the short-term and midterm results of open and endoluminal repair of abdominal aortic aneurysms (AAA) in a large single-center series and specifically in octogenarians. patients underwent elective repair of AAA. Conventional open repair (COR) was performed in 210 patients and endoluminal graft (ELG) repair in 260 patients. Ninety of the patients were 80 years of age or older; of these, 38 underwent COR and 52 ELG repair.
Objective
To analyze the short-term and midterm results of open and endoluminal repair of abdominal aortic aneurysms (AAA) in a large single-center series and specifically in octogenarians.
Methods
Between January 1997 and October 2000, 470 consecutive patients underwent elective repair of AAA. Conventional open repair (COR) was performed in 210 patients and endoluminal graft (ELG) repair in 260 patients. Ninety of the patients were 80 years of age or older; of these, 38 underwent COR and 52 ELG repair.
Results
Patient characteristics and risk factors were similar for both the entire series and the subgroup of patients 80 years or older. The overall complication rate was reduced by 70% or more in the ELG versus the COR groups. The postoperative death rate was similar for the COR and ELG groups in the entire series and lower (but not significantly) in the ELG 80 years or older subgroup versus the COR group. The 36month rates of freedom from endoleaks, surgical conversion, and secondary intervention were 81%, 98.2%, and 88%, respectively.
Conclusion
The short-term and midterm results of AAA repair by COR or ELG are similar. The death rate associated with this new technique is low and comparable, whereas the complication rate associated with COR in all patients and those 80 years or older in particular is greater and more serious than ELG repair. Long-term results will establish the role of ELG repair of AAA, especially in elderly and high-risk patients.
Fifty years ago Charles Dubost performed the first successful repair of an infrarenal abdominal aortic aneurysm (AAA). 1 Although a significant decrease in the surgical death rate for elective repair of AAA has been achieved during the past five decades, the complication rate for conventional open repair (COR) remains significant. [2] [3] [4] [5] In 1991, Parodi et al 6 reported the first successful repair of an infrarenal AAA using an endoluminal graft (ELG). Like any new technologic advance, this less-invasive technique for aneurysm repair is undergoing intensive scrutiny to determine its role in the treatment of this common vascular condition. Although investigators using a variety of firstand second-generation aortic ELG devices have shown excellent early and midterm results, 7-10 others have urged caution in the widespread use of this technology while it is still in evolution. 11 The impact of minimally invasive procedures on surgical death and complication rates deserves special attention, particularly in the aging population. Octogenarians are becoming an increasingly important proportion of the popu-lation, and many of them will need surgical care. 12, 13 Minimally invasive surgical procedures have been shown to affect outcomes and postoperative quality of life significantly. 14 Although conventional elective procedures can be performed with acceptable death rates in octogenarians (albeit higher than in younger patients), the surgical complication rate remains considerable. 15, 16 Despite the abundant growing literature on treatment of AAAs with ELGs, no previously published series has specifically examined the potential benefits that elective ELG repair might have in patients 80 years or older when compared with conventional open repair (COR).
PATIENTS AND METHODS
From January 1997 through October 2000, 470 consecutive patients underwent elective repair of an infrarenal aortic aneurysm. Of these, 210 (44.6%) underwent COR and 260 ELG repair. COR was performed by either a left flank retroperitoneal (80%) or a midline transabdominal (20%) approach. Ninety patients (19%) were 80 years or older; of these, 38 (42.7%) underwent COR (transabdominal 20, retroperitoneal 18) and 52 (57.3%) ELG repair. The mean age was 72.6 Ϯ 8 years (range 42-90) for the COR group and 71.9 Ϯ 9 years (range 50 -92) for the ELG group. For the subset of patients 80 years or older, the mean age was 82.6 Ϯ 3 years (range 80 -93) for those undergoing COR and 83.2 Ϯ 3 years for those undergoing ELG repair. By the American Society of Anesthesiology (ASA) risk classification criteria, there were no significant differences between patients in the whole group nor for those in the subgroup 80 years or older; overall, 85% to 95% of the patients were considered ASA grade 3 or 4 ( Table 1) . The presence and severity of preoperative risk factors (Table 2) were also similar in all groups, except for coronary artery disease, which was significantly greater in the ELG group (P ϭ .04), and the incidence of renal insufficiency (Ն2.0 mg/dL), which was greater in the COR group (P ϭ .04). All risk factors were similar in the group 80 years or older whether the AAA repair was performed by COR or ELG.
If the aneurysmal anatomy was unsuitable for ELG repair with currently available devices, COR was performed. Patients 70 years or younger and considered low risk for surgery were strongly advised to undergo COR. In addition, patients who were not likely to adhere to the strict follow-up schedule required for this evolving technology were not considered for ELG repair. Iliac artery anatomy was not a major factor for exclusion except in patients with very small (Ͻ6 mm) iliac arteries bilaterally that precluded endograft insertion. The surgical approach used in patients undergoing COR was based on the surgeon's preference, with 80% of open operations performed through a retroperitoneal exposure.
Patients were selected for ELG treatment if they met the following anatomic inclusion criteria: proximal aortic neck of 25.5 mm or less in diameter and 10 mm or greater in length, and 60°or less in aortic neck angulation. The ELG devices used in this series included AnCure/EVT graft (Guidant, Menlo Park, CA) in 75 (29%) patients, the An-euRx graft (Medtronic/AVE, Santa Rosa, CA) in 158 (61%) patients, and the Excluder graft (W.L. Gore & Associates, Flagstaff, AZ) in 27 (10%) patients. In the 52 patients 80 (Table 3 ). Of the total endoluminal experience, 232 (89%) patients had a bifurcated endoluminal graft (see Table 1 ). The other 28 patients had AnCure/ EVT grafts. Seventeen patients had tube grafts and 11 had aortouniiliac grafts with contralateral common iliac occlusion and femorofemoral bypass. Seventy-one (95%) of the AnCure/EVT grafts, as well as all of the Excluder aortic endografts, were placed during the conduct of phase II Food & Drug Administration (FDA) trials. Four patients underwent insertion of bifurcated AnCure/EVT ELGs after FDA approval, and all AneuRx grafts were used after FDA market approval. All ELG repairs were performed in the operating room using C-arm technology for fluoroscopic guidance during insertion and deployment of the ELG. Longitudinal (initial experience) or transverse inguinal incisions were used for femoral vessel control. Transfemoral insertion of the ELG was achieved in 257 (98.8%) patients, with 3 patients requiring placement of a Dacron iliac artery conduit for ELG insertion as a result of small external iliac arteries. The mean follow-up for the COR group and the total ELG series was 26.2 Ϯ 14 months and 17.2 Ϯ 12 months, respectively. In the subgroup of patients 80 years or older, the follow-up was similar to that of the total group (25.2 Ϯ 14 months for the COR group and 16.6 Ϯ 12 months for the ELG group).
The criteria for success (technical and clinical) of ELGs were based on the definitions established in the reporting standards for endovascular AAA repair published by the Ad Hoc Committee of the Joint Vascular Societies. 15 Technical success for ELG AAA repair was defined as procedures completed from a remote arterial site with successful proximal and distal attachment fixation without persistent perigraft endoleak and without any other periprocedural major arterial complications. Technical success for open AAA repair was defined as a successfully completed procedure without need for reoperation and with patient survival at 30 days. Clinical success was defined as the absence of aneurysm expansion or rupture, as well as closure of any early endoleak within 6 months. Major complications were defined as any complication requiring a prolonged hospital stay, unplanned surgical reintervention, the need for intravenous therapy secondary to ileus, pharmacotherapy for arrhythmias, or the need to administer intravenous antibiotics.
Patient data were placed in an Excel spreadsheet. All analyses were performed with SAS Version 8.1 (SAS Institute Inc., 1999, Cary, NC). Analyses based on data in a set of rectangular tables were analyzed by the Cochran-Mantel-Haenzel chi-square (surgical complications, death, ASA). When the independent variable had two levels, the Wilcoxon chi-square test was used (estimated blood loss, intensive care unit days, hospital length of stay), and the Kruskal-Wallis test was used when indicated. P Յ .05 was considered significant. Survival curves (patient survival, freedom from endoleaks, freedom from conversion, and freedom from intervention) were generated by Kaplan-Meier analysis.
RESULTS
The patient characteristics were statistically similar between the groups undergoing COR versus ELG, both for the entire group (n ϭ 470) and for the subgroup of patients 80 years or older; the sole exception to this was aneurysm size, which was significantly larger in the COR group (P ϭ .001) (see Table 1 ). Preoperative risk factors were also similar for those undergoing COR versus ELG except for the incidence of coronary artery disease, which was significantly greater Aortic Aneurysm Repair: Open Versus Endoluminal in the patients 80 years or older who underwent ELG repair (see Table 2 ). Operative times were equivalent for patients undergoing COR versus ELG repair, both in the total series and in the subgroup of patients 80 years or older. Estimated blood loss, mean intensive care unit stay, and total hospital length of stay were all significantly lower for the ELG group versus the COR group, both for the entire series and for the subgroup of patients 80 years or older (P Ͻ .0001) ( Table  4 ). In addition, a greater number of major complications occurred in the COR group than in the ELG group, both in the total series and in the 80 years or older group (P Ͻ .0001 and .0043, respectively) ( Table 5 ). There was no significant difference in perioperative and postoperative complications based on the type of ELG used in the total group or in those 80 years or older. Cardiac complications represented the main postoperative complication in the total COR group as well as in the subgroup of patients 80 years or older (32% and 50%, respectively). In contrast, the main complications observed in the ELG groups were vascular and wound-related. Vascular complications included endograft limb thrombosis that required urgent thrombectomy or revision; the wound complications were largely lymphoceles (n ϭ 5) and superficial wound infections (n ϭ 3). All lymphoceles underwent successful surgical resolution. Superficial wound infections were treated with intravenous antibiotics and local care.
The overall death rate in patients undergoing ELG repair was 1.9%, both in the total series and in the subgroup of patients 80 years or older. This compared favorably with the death rates in patients undergoing COR (2.9% in the total series and 5.3% in patients 80 years or older), although these differences did not reach statistical significance. The 3-year survival rate for patients undergoing ELG was not statistically significant when compared with patients undergoing COR (91.2% ELG vs. 86.2% COR for the total series; 90.1% ELG vs. 83.1% COR for patients 80 years or older; Figs. 1, 2).
Freedom from endoleaks for patients undergoing ELG was 88%, 82%, 81%, and 81% at 1, 12, 24, and 36 months, respectively (Fig. 3) . A total of 34 (13%) endoleaks (7 type 1, 27 type 2) were detected in the entire endoluminal series ( Table 6 ). Of the 27 type 2 endoleaks, 14 (67%) resolved spontaneously within 6 to 12 months. Five patients have undergone successful endoluminal embolization (three inferior mesenteric arteries and two lumbar arteries). Eight patients have persistent type 2 lumbar endoleaks with no evidence of aneurysm growth. Of these eight patients, five had a decrease in aneurysm size and three remain unchanged. These three patients are being followed every 6 months with computed tomography scans. All type 1 endoleaks (n ϭ 7) were addressed immediately, either by endoluminal approaches (n ϭ 6) or by open extension of an iliac artery limb (n ϭ 1). Late endoleaks (Ͼ6 months) were detected in 13 patients (11 type 2, 2 type 1). The two patients with late-appearing type 1 endoleaks were successfully treated using endoluminal approaches, one by a proximal cuff extension ( Fig. 4 ) and the other by endoluminal conversion of a tube graft to a bifurcated graft for a distal attachment type 1 endoleak that arose 45 months after the primary repair. Four of 11 patients with late type 2 endoleaks resolved spontaneously and 7 patients have persistent endoleaks. These patients have exhibited no aneurysm growth and are being followed up closely with computed tomography scans. Technical success was achieved in 197 (94%) and 215 (81%) patients in the COR and ELG groups, respectively (P Ͻ .001). Reexploration for bleeding (n ϭ 6), limb thrombectomy (n ϭ 1), and death (n ϭ 6) accounted for the COR failures. Failures in the ELG group included 34 patients with early (1 month) endoleaks, 4 patients requiring reoperation for acute limb thrombosis, 2 patients requiring open conversion during surgery for incorrect deployment, and 5 patients dying within 30 days. The 36-month rate of freedom from surgical conversion was achieved in 98.2% of the ELG group (Fig. 5 ). In the 80 year or older group, the technical success rate was 94.7% in the COR group and 
DISCUSSION
Elective open AAA repair remains a safe and durable procedure with a relatively low risk of surgical death. Postoperative death rates for open aneurysm repair range from 0% to 4% for single-center reports [17] [18] [19] to approximately 7.0% for population-based reports. 20 -23 Advanced age is a factor associated with increased rates of surgical death and complications in aneurysm repair. 24 -27 In a populationbased study, Dardik et al 23 recently reported an in-hospital death rate for elective AAA repair of 3.5%. Of note is the significant increase in the death rate with advancing age, ranging from 2.2% for patients in the sixth decade of life to 7.3% for octogenarians. As life expectancy increases in developed countries, the complexity of surgical therapy in the elderly becomes an increasing concern and calls for less-invasive surgical treatment. Issues of life expectancy, risks of the procedure, and postoperative quality of life play an important role in the patient's, surgeon's, and anesthesiologist's decision. This concern is highlighted by the fact that there are currently at least 4 million octogenarians in the United States, a figure expected to grow as high as 30 million by 2050. 28 Recent studies have addressed the outcomes of patients determined to be unsuitable for open repair, confirming the significant incidence of deaths attributable to aneurysm rupture in this high-risk group. 29, 30 An important observation has been the significant rate of rupture-related deaths in this high-risk group. Conway et al 29 Aortic Aneurysm Repair: Open Versus Endoluminal also increased significantly from 36% in patients with AAA smaller than 6 cm to 50% and 55% for aneurysms 6 to 7 cm and larger than 7 cm, respectively. In a similar series, Jones et al 30 reported on 50 patients (mean age 81 years) turned down for elective surgery; a ruptured aneurysm was the ultimate cause of death in 38%. In our series, mean aneurysm size in patients 80 years or older was 6.4 ϩ 2 cm in the COR group and 5.9 ϩ 2 cm in the ELG group. This is a larger aneurysm size than was found in the entire series (5.8 ϩ 1.5 cm in the COR group, 5.5 ϩ 1 cm in the ELG group). This larger size that we observed in octogenarians may reflect a common tendency by referring physicians to delay referral of patients in this age group for surgical repair. Many series have reported acceptable death rates for elective AAA repair in octogenarians (Table 7) . Not only is the death rate greater compared with patients younger than 80 years of age, but the postoperative complication rate remains significant. 23, [31] [32] [33] Although age has been found by some investigators to be an independent factor predictive of increased complications in aneurysm repair, 27 most authors agree that the increased risk factors commonly found in the elderly are what determines the worse outcome. [25] [26] [27] [28] 34, 35 In view of the substantial rupture-related death rate that is associated with expectant treatment of AAAs in octogenarians, it makes sense to critically evaluate ELG treatment as a less-invasive option. Most contemporaneous series have shown a lower but not significantly different surgical death rate for ELG treatment of AAAs. 7,8,36 -40 The benefits of endoluminal aortic grafts over open repair are primarily fewer postoperative complications and, therefore, a shorter hospital length of stay. The 3.4% postoperative death rate in our series for the total COR group and for patients 80 years or older compares favorably with reported series. [23] [24] [25] 32, 36 In a large series of elective aneurysm repairs in octogenarians, O'Hara et al 24 reported an overall death rate of 9.6% in a 10-year period from 1984 to 1993, with a decrease from 17% to 4% in the second 5 years of treatment. The surgical death rate for the ELG patients was 1.9% for both groups, similar to contemporary series. 7,8,36 -39 In our series, the overall complication rate was reduced by 70% or more in the ELG groups. Cardiac problems are a common cause of perioperative and postoperative deaths and complications in open aneurysm repair. 18, 24, 25, 34, 35 In our series, cardiac complications occurred in 30% of the COR group overall and in 50% in the COR patients 80 years or older. In contrast, cardiac complications occurred in only 1.9% of the ELG group overall and 3.8% of the ELG patients 80 years or older. This marked decrease in cardiac complications reflects the lower invasiveness of the ELG technique.
Vascular complications occurred with similar frequency in both the COR and ELG groups. Peripheral atheroembolism was the most frequent vascular complication in the COR group; graft limb thrombosis was the most frequent vascular complication in the ELG group. All graft limb thromboses were successfully resolved transfemorally using endoluminal techniques; the peripheral atheroembolism in the COR group could be managed only expectantly. No major limb amputations were necessary in either group.
Gastrointestinal complications are common in the transabdominal approach to AAA repair. Postoperative prolonged ileus has been reported as a complication of open AAA repair in 4% to 11% in randomized trials comparing transabdominal with retroperitoneal approach for AAA repair. 40 -42 In our series, 8 (3.8%) of 210 patients who underwent COR had a gastrointestinal complication (see Table 4 ). Prolonged ileus occurred in only five (2.4%) patients, reflecting the low incidence of this complication in patients undergoing retroperitoneal AAA repair. Two patients had postoperative obstruction requiring reoperation for adhesiolysis, and one patient had mild ischemic colitis; this patient recovered with conservative management. No ischemic colitis occurred in the 80 years or older ELG group. Recent publications of results of different endografts have reported a 3% to 6% incidence of gastrointestinal complications but no ischemic colitis. [37] [38] [39] We reviewed carefully the preoperative as well as completion arteriograms in all of our patients with ischemic colitis and did not detect any anatomic reason for this serious complication. Endoleaks are unique complications that occur after ELG repair of AAAs. The rates of endoleaks and endoleak-free survival in our series, for the total group and the 80 years or older group, are comparable with those of published series, suggesting that this technique may be applicable to the older population. Nevertheless, the evaluation and treatment of endoleaks and poor graft fixation with all endovascular devices are topics of continued discussion and evolution. 39 We have been very attentive to patient follow-up and intervened aggressively when considered necessary. The 36month rates of freedom from endoleaks, surgical conversion, and secondary interventions were 81%, 98.2%, and 88%, respectively ( Figs. 4 -6 ). Fortunately, we have not had an aneurysm rupture during follow-up to date, which is the ultimate goal of endovascular and open aneurysm exclusion.
In conclusion, the results of aneurysm exclusion by open or endovascular means with available devices is similar at short-term and midterm follow-up. The death rate associated with these procedures is low and comparable; the complication rate associated with open surgical repair in all patients, and those 80 years or older in particular, is greater and more serious than with endovascular repair. The growing population of patients with AAAs will benefit from the use of endovascular and other less-invasive techniques for the treatment of this lethal condition. We need to continue to critically evaluate new devices and techniques that become available to ensure that our patients will benefit from these advances. This will require close long-term and most likely lifetime follow-up of our patients, with measured interventions when necessary. The growing elderly population is likely to benefit the most from these evolving endovascular techniques, with decreased perioperative complications and an improved quality of life for the rest of their lives.
Discussion
DR. FRANK J. VEITH (Bronx, New York): I applaud Dr. Sicard's analysis of the safety and value of endovascular graft repair of abdominal aortic aneurysms in 80-year-old and high risk patients.
We have been performing endovascular aortic and aortoiliac aneurysm repairs for 9.5 years, since we did the first such operation in the U.S. in 1992. That procedure was performed in a very high risk patient, and 75% of our 315 endovascular aortoiliac aneurysm repairs have been in patients considered high or prohibitive risks for open repair. Many have been over 80. Some have been over 90.
We have some areas of agreement and some mild disagreements with Dr. Sicard's points.
First, we agree that endovascular repairs are particularly indicated in high risk and elderly patients where protracted periods of success may not be so critical. As Dr. Ohki will point out shortly, we have noted an increasing incidence of late complications after aortic endografting. That means that caution should be applied in using these techniques to treat AAAs in good risk, relatively young patients. However, graft improvements will inevitably, I believe, overcome this requirement for caution and allow us to extend our indications. Even now most of the late problems we see can be managed endovascularly with a fairly benign intervention, as Dr. Sicard also noted.
Second, we agree that younger healthy patients should be encouraged to have an open operation until we have more long-term data. Widespread use of endovascular repair probably should be preceded by a randomized prospective comparison with open repair, even though such studies will be hard to carry out because many patients will opt for the less invasive procedure and refuse randomization.
Finally, and I am sure this is a surprise to some, I do not agree that all AAAs over 5.5 centimeters have to be fixed because their rupture rate is as high as some, including Dr. Sicard and others (Conway et al) believe it to be. We have now followed a group of 72 patients with serious co-morbidities and AAAs 5.6 to 12 centimeters for 6 to 76 months, or a mean of two years. Although 53 of the 72 patients ultimately had their aneurysm repaired after 6 to 72 months of observation, only 3 of the 72 patients, or 4%, died from a rupture of their aneurysm. Three times as many of these patients, or 9%, died from their co-morbidities. Thus, not every large aneurysm has to be treated right away.
Moreover, with these extremely high risk patients, it is probably justified to do a randomized prospective comparison between endovascular repair and best medical treatment. And such a study is being planned in Britain and another in Holland. Dr. Sicard, what are your thoughts about such prospective studies? PRESENTER. DR. GREGORIO A. SICARD (St. Louis, Missouri): Thank you. I appreciate Dr. Veith's comments. As you all know, Dr. Veith has been a pioneer in the field of endoluminal treatment of abdominal aortic aneurysms, and you will be hearing the presentation from his institution's 9.5-year experience shortly.
Regarding randomized prospective studies, it is hard to argue against performing randomized clinical trials, specially when we are trying to determine the role of this procedure in the treatment Vol. 234 • No. 4 Aortic Aneurysm Repair: Open Versus Endoluminal of patients with AAAs. As you point out though, patient's preference has become a very strong factor in the treatment decision. I would strongly support this concept and our institution would be a participant in a trial such as this, although I think it would be very difficult.
The 80-year-old patient is a different situation, as well as, is the high-risk patient. Sometimes we cannot offer them open repair. We all have patients that anatomically are not suited for any endovascular device that is commercially available and becausse of medical risk factors, they have to be turned down for any therapeutic modality.
On the other hand, patients that are 80 years of age have an 8.5-year life expectancy. I think it is hard to ignore a 6 cm aneurysm and not offer them endoluminal treatment if anatomically feasible. In our series of 80-year-old patients, the mean size was 6 cm, which might reflect a referral from primary care physicians that send us the octogenarian when the aneurysm size is larger than in the younger patients.
I think that to the 80-year-old patient, we do should offer some technique if they have this type of life expectancy. On the other hand, if it is an 80-year-old patient that has a 12-month life expectancy, obviously, medical therapy or just expectant therapy is preferred.
I fully agree with Dr. Veith that a randomized trial will be the only way that we would resolve this important question of comparable efficacy. Unfortunately, this is a moving target, the technology is evolving very quickly and industry continues to make changes in the devices that we hope are for the best.
DR. LARRY H. HOLLIER (New York, New York): I would like to thank Dr. Sicard and his group for sending me a copy of their paper and asking me to discuss this. In my view, this paper is probably the best comparison to date of open versus endovascular aneurysm repair in a large group of patients. It is really a superbly written paper and I commend it to all of you.
I think what is most interesting about this paper is that, contrary to common belief by referring physicians and patients, the mortality rate associated with endovascular repair is not statistically different from that of open repair. And your paper demonstrated that quite clearly. What is evident, however, is that in all patients, and particularly in the elderly, the time of recovery from aneurysm repair is dramatically shorter than those undergoing endovascular repair.
What is not evident in this paper, however, are the late complications occurring over time. In over 400 patients who have had endovascular repair for infrarenal aneurysms over the last four years at our institution, we are starting to see an increasing number of migrations now at three and four years, and the late failure rates due to endoleaks are rising.
Your duration of follow-up in the 80-year-olds is relatively short. I think in three years there were only eight patients with late failure if I saw your slide correctly. I am asking you if you might have some better insight than evident in the paper about the etiology of the increasing rate of late failures.
If you start with a patient at 80 years old, who has 8.5 years expected actuarial survival, he has got a great chance of further complications and secondary repair might be more complicated. Maybe you could enlighten us about the late follow-up.
DR. GREGORIO A. SICARD (St. Louis, Missouri): I think that Dr. Hollier brings out a key point in the endoluminal treatment of aortic aneurysms, which I am sure will be expanded on in the next presentation. This is the issue of material fatigue and related adverse events that occur. These events tend to occur more frequently after 3-5 years of implantation.
The mean follow-up for the endoluminal group in our series is around 17 months, which falls below the line where other groups are reporting failures. What this tells us is that we have to watch the patients very carefully. It is important to inform our patients that we don't know the long-term results with these devices and that they need to keep to the surveillance follow-up schedule closely.
So far, in our series, we have seen three late adverse events: one patient developed an endotension that required open repair which was listed in the conversion rate slide and two patients have developed an increase in the size of the aneurysm due to Type II endoleaks. Both of these have been successfully treated by endoluminal means, in one case by a translumbar technique with coils and the other by the use of glue into the lumbar artery.
It becomes very important that anyone performing this type of endoluminal aortic procedure understand the significance of the surveillance problems in order to identify the potential late failures and hopefully, offer the patients an endoluminal solution.
DR. WILLIAM D. TURNIPSEED (Madison, Wisconsin): A comment and a couple of questions. First, I would like to thank the Program Committee for allowing the vascular surgical component of the program to be expanded at the American Surgical. I hope all of you appreciate it and will follow with interest.
Dr. Sicard, since Juan Parodi introduced the concept of endoaortic stent grafting, proposed advantages for its use were: reduced morbidity and mortality; ease of recovery, and shorter hospital stay. Some of these goals have been accomplished, particularly reduction in hospital stay.
What has not yet occurred is significant reduction in mortality. To my knowledge, this is the first and only paper that has statistically shown an improved morbidity. Other studies have demonstrated trends in morbidity reduction, but statistical differences between open and closed have really not been shown in any of the phase 2 trials or the clinical updates.
If endografts are to be used primarily for high risk situations, what exactly is your definition of high risk? You mentioned severe cardiac disease as a high risk. What are the other factors which determine high risk? I think it is very important when we use the argument of increased risk to define the term precisely.
If you look in the literature, there are a number of alternative less invasive approaches for the management of aortic disease right now. One that we espouse is the minimal incision aortic approach. Laparoscopically assisted open or closed laparoscopic retroperitoneal approaches have been proposed as well. They all show exactly the same results: improved morbidity, reduced hospital stay with no change or improvement in mortality studies. These results are not dissimilar to those achieved by endovascular techniques.
What do you do in the circumstance of a high risk patient that has bad anatomy for an endovascular graft? Do they get the old-fashioned operation? Or would you use one of these other alternatives for the treatment of these patients?
DR. GREGORIO A. SICARD (St. Louis, Missouri): Thank you, Dr. Turnipseed. I appreciate your comments.
Just to be brief, I think that all the other procedures besides the endoluminal approach and especially the transabdominal approach, have a high incidence of prolonged ileus and other gastrointestinal complications. This is one of the complications that is significantly diminished by endovascular or endoluminal techniques.
The risk definition in our series was based on the fact that 60% of our patients had a history of coronary artery disease and were classified as ASA risk classification of 3 or 4, with around 20% of these being a risk 4. We did not fine-tune it more, which I think, would probably would be important to do in further studies.
Is it a cost-effective procedure at this point? I think the answer is no, it is more expensive than the open repair if dollars are based on the added payment because of complications. What we can offer with the endoluminal technique of AAA repair, especially in the elderly, is an operation that has minimum morbidity and very low mortality. Furthermore, the types of complications are significantly different than in the open repair. These elderly patients can go home in a couple of days rather than going to a nursing home after being in the hospital for a prolonged period of time.
In conclusion, the endoluminal repair of AAA in the elderly is a procedure or a technique that requires further evaluation, preferably with randomized trials. I still think that the endoluminal repair is a better option than open repair. 
